CR11418A - Trans-clomifeno para el sindrome metabolico - Google Patents
Trans-clomifeno para el sindrome metabolicoInfo
- Publication number
- CR11418A CR11418A CR11418A CR11418A CR11418A CR 11418 A CR11418 A CR 11418A CR 11418 A CR11418 A CR 11418A CR 11418 A CR11418 A CR 11418A CR 11418 A CR11418 A CR 11418A
- Authority
- CR
- Costa Rica
- Prior art keywords
- clomphene
- trans
- metabolic syndrome
- antiestrogen
- subject
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Abstract
La presente invencion se relaciona con un metodo de tratamiento del sindorme metabolico que comprende administrarle a un sujeto que lo necesita, una composicion que comprende una cantidad eficaz de un antiestrogeno o una sal aceptable para uso farmaceutico del mismo.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US98033407P | 2007-10-16 | 2007-10-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
CR11418A true CR11418A (es) | 2010-08-24 |
Family
ID=40023452
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR11418A CR11418A (es) | 2007-10-16 | 2010-05-07 | Trans-clomifeno para el sindrome metabolico |
Country Status (25)
Country | Link |
---|---|
US (2) | US8372887B2 (es) |
EP (2) | EP2826475B1 (es) |
JP (4) | JP5558358B2 (es) |
KR (1) | KR101493472B1 (es) |
CN (2) | CN102940619A (es) |
AR (1) | AR069541A1 (es) |
BR (1) | BRPI0818637A2 (es) |
CA (3) | CA2702710C (es) |
CL (1) | CL2008002999A1 (es) |
CO (1) | CO6270215A2 (es) |
CR (1) | CR11418A (es) |
EA (2) | EA017385B1 (es) |
EC (1) | ECSP10010106A (es) |
ES (1) | ES2718912T3 (es) |
HK (1) | HK1150023A1 (es) |
IL (1) | IL205053A (es) |
ME (1) | ME00996B (es) |
MX (1) | MX2010004195A (es) |
MY (1) | MY150082A (es) |
NI (1) | NI201000053A (es) |
NZ (2) | NZ591955A (es) |
SG (1) | SG185311A1 (es) |
TW (1) | TW200918093A (es) |
UA (1) | UA96076C2 (es) |
WO (1) | WO2009051908A1 (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003005954A2 (en) | 2001-07-09 | 2003-01-23 | Zonagen, Inc. | Methods and materials for the treatment of testosterone deficiency in men |
US7737185B2 (en) | 2001-07-09 | 2010-06-15 | Repros Therapeutics Inc. | Methods and compositions with trans-clomiphene |
EP1865938A4 (en) | 2005-03-22 | 2008-09-24 | Repros Therapeutics Inc | DOSAGE SCHEMES FOR TRANS-CLOMIPHENE |
CN102940619A (zh) | 2007-10-16 | 2013-02-27 | 利普生物药剂公司 | 用于治疗代谢综合征的珠氯米芬 |
TW201500041A (zh) * | 2008-11-07 | 2015-01-01 | Repros Therapeutics Inc | 用於代謝症候群與第2型糖尿病的反式氯米芬 |
NZ609420A (en) * | 2010-09-16 | 2015-06-26 | Shimoda Biotech Pty Ltd | Fulvestrant compositions and methods of use |
UA113291C2 (xx) | 2011-08-04 | 2017-01-10 | Метаболіти транскломіфену і їх застосування | |
US20150031656A1 (en) * | 2012-02-29 | 2015-01-29 | Repros Therapeutics Inc. | Combination therapy for treating androgen deficiency |
WO2014031177A1 (en) | 2012-08-21 | 2014-02-27 | Repros Therapeutics Inc. | Trans-clomiphene formulations and uses thereof |
WO2014070523A1 (en) | 2012-11-02 | 2014-05-08 | Repros Therapeutics Inc. | Trans-clomiphene for use in cancer therapy |
US20160051565A1 (en) * | 2014-08-20 | 2016-02-25 | Professional Compounding Centers Of America (Pcca) | Transdermal Pharmaceutical Compositions Including Testosterone and an Aromatase Inhibitor |
US20160051495A1 (en) * | 2014-08-20 | 2016-02-25 | Professional Compounding Centers Of America | Oral Transmucosal Compositions including C-SERMs for Low Testosterone Levels in Men |
WO2016089904A1 (en) * | 2014-12-02 | 2016-06-09 | Repros Therapeutics Inc. | Trans-clomiphene and its analogues as agents for treating or preventing filovirus diseases |
EP3167869A1 (en) | 2015-11-16 | 2017-05-17 | Capsugel Belgium NV | Tamperproof oral dosage form |
EP3167870B1 (en) | 2015-11-16 | 2024-01-03 | Capsugel Belgium NV | Tamperproof oral dosage form |
RU2611936C1 (ru) * | 2016-02-16 | 2017-03-01 | Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии и регенеративной медицины имени Е.Д. Гольдберга" | Способ моделирования гипогонадизма, вызванного метаболическими нарушениями |
JP2019506425A (ja) * | 2016-02-25 | 2019-03-07 | アスペン パーク ファーマシューティカルズ,インコーポレイティド | クロミフェン異性体の経口剤形および続発性性腺機能低下症を治療するために経口剤形を使用する方法 |
Family Cites Families (105)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2464203A (en) | 1943-05-21 | 1949-03-15 | Boots Pure Drug Co Ltd | Manufacture of dienoestrol |
US2465505A (en) | 1944-12-05 | 1949-03-29 | Hoffmann La Roche | Process for the manufacture of 3, 4-di-(p-hydroxy-phenyl)-hexadiene-2, 4 |
US2914562A (en) | 1957-08-06 | 1959-11-24 | Wm S Merrell Co | Amine derivatives of triphenylethanol |
BE637389A (es) | 1962-09-13 | |||
US3822287A (en) | 1969-04-17 | 1974-07-02 | Rexall Drug Chemical | Process for preparation of substituted 3,4-(diphenyl)chromans |
US4230862A (en) | 1975-10-28 | 1980-10-28 | Eli Lilly And Company | Antifertility compounds |
US4133814A (en) | 1975-10-28 | 1979-01-09 | Eli Lilly And Company | 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents |
US4061733A (en) | 1976-10-15 | 1977-12-06 | Narayan Vishwanath Gunjikar | Veterinary compositions for inducing estrus in animals and method |
DE2658307C2 (de) | 1976-12-22 | 1979-03-15 | Klinge Pharma Gmbh & Co, 8000 Muenchen | Di-O'-hydroxyphenyD-alkanverbindungen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
DE2860900D1 (en) | 1977-08-22 | 1981-11-05 | Ici Plc | Triphenylalkene derivatives, process for their preparation and pharmaceutical compositions containing them |
DE3046719C2 (de) | 1980-12-11 | 1983-02-17 | Klinge Pharma GmbH, 8000 München | 1,1,2-Triphenyl-but-1-en-Derivate, Verfahren zu ihrer Herstellung und Arzneimittel |
US4418068A (en) | 1981-04-03 | 1983-11-29 | Eli Lilly And Company | Antiestrogenic and antiandrugenic benzothiophenes |
FR2521565B1 (fr) | 1982-02-17 | 1985-07-05 | Dior Sa Parfums Christian | Melange pulverulent de constituants lipidiques et de constituants hydrophobes, procede pour le preparer, phases lamellaires lipidiques hydratees et procede de fabrication, compositions pharmaceutiques ou cosmetiques comportant des phases lamellaires lipidiques hydratees |
GB2126576B (en) | 1982-06-25 | 1985-06-19 | Farmos Group Limited | Alkane and alkene derivatives |
US5491173A (en) | 1982-06-25 | 1996-02-13 | Orion-Yhtyma Oy | Tri-phenyl alkene derivatives and their preparation and use |
FR2534487B1 (fr) | 1982-10-15 | 1988-06-10 | Dior Christian Parfums | Procede d'homogeneisation de dispersions de phases lamellaires lipidiques hydratees, et suspensions obtenues par ce procede |
GB8327256D0 (en) | 1983-10-12 | 1983-11-16 | Ici Plc | Steroid derivatives |
IE58417B1 (en) | 1984-04-27 | 1993-09-22 | Ici Plc | Chemical derivatives |
US4729999A (en) | 1984-10-12 | 1988-03-08 | Bcm Technologies | Antiestrogen therapy for symptoms of estrogen deficiency |
EP0206021B1 (de) | 1985-06-08 | 1988-08-10 | ASTA Pharma AG | Neue Derivate des 1,1,2,2-Tetramethyl-1,2-bis-(2-fluor-4-hydroxyphenyl)-ethans |
GB8517360D0 (en) | 1985-07-09 | 1985-08-14 | Erba Farmitalia | Substituted androsta-1,4-diene-3,17-diones |
US5352795A (en) | 1986-03-07 | 1994-10-04 | Ciba-Geigy Corporation | Alpha-heterocycle substituted tolunitriles |
DE3762617D1 (de) | 1986-09-11 | 1990-06-13 | Nat Res Dev | Tamoxifenderivate. |
US4820736A (en) | 1987-03-20 | 1989-04-11 | Yale University | Use of clomiphene to predict fertility in a human female |
GB8714013D0 (en) | 1987-06-16 | 1987-07-22 | Ici Plc | (substituted-aralkyl)heterocyclic compounds |
US5077211A (en) | 1988-07-06 | 1991-12-31 | Applied Genetics, Inc. | Purification and administration of dna repair enzymes |
US5395842A (en) | 1988-10-31 | 1995-03-07 | Endorecherche Inc. | Anti-estrogenic compounds and compositions |
GB8926171D0 (en) | 1989-11-20 | 1990-01-10 | Applied Research Systems | Treatment of infertility |
JPH04312522A (ja) | 1991-04-08 | 1992-11-04 | Yoshiaki Kawashima | 徐放性錠剤の製造方法 |
US6060503A (en) | 1991-12-02 | 2000-05-09 | Endorecherche, Inc. | Benzopyran-containing compounds and method for their use |
US5681585A (en) | 1991-12-24 | 1997-10-28 | Euro-Celtique, S.A. | Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer |
US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
EP0639567A1 (en) | 1992-05-08 | 1995-02-22 | Otsuka Pharmaceutical Factory, Inc. | Indole derivative |
TW366342B (en) | 1992-07-28 | 1999-08-11 | Lilly Co Eli | The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss |
US5776923A (en) | 1993-01-19 | 1998-07-07 | Endorecherche, Inc. | Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone |
US6756388B1 (en) | 1993-10-12 | 2004-06-29 | Pfizer Inc. | Benzothiophenes and related compounds as estrogen agonists |
GB9326332D0 (en) | 1993-12-23 | 1994-02-23 | Karo Bio | Indole derivatives |
GB9405304D0 (en) | 1994-03-16 | 1994-04-27 | Scherer Ltd R P | Delivery systems for hydrophobic drugs |
JP2964871B2 (ja) | 1994-04-20 | 1999-10-18 | ノーリツ鋼機株式会社 | ネガマスク装置 |
US5681835A (en) | 1994-04-25 | 1997-10-28 | Glaxo Wellcome Inc. | Non-steroidal ligands for the estrogen receptor |
WO1995035093A1 (en) | 1994-06-17 | 1995-12-28 | University Of Nebraska Board Of Regents | In situ gel-forming delivery vehicle for bio-affecting substances, and method of use |
DE4426625A1 (de) | 1994-07-27 | 1996-03-14 | Schering Ag | 2-Phenylindole, Verfahren zu deren Herstellung, diese enthaltende pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln |
DE4435368A1 (de) | 1994-09-22 | 1996-03-28 | Schering Ag | Verwendung von Aromatasehemmern zur Herstellung eines Arzneimittels zur Behandlung eines relativen Androgenmangels beim Mann |
US5552412A (en) | 1995-01-09 | 1996-09-03 | Pfizer Inc | 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis |
WO1997006787A2 (en) | 1995-08-17 | 1997-02-27 | Dyer, Alison, Margaret | Controlled release products |
US5883118A (en) | 1996-01-11 | 1999-03-16 | Nova Nordisk A/S | Prostatic carcinoma |
IL124881A0 (en) | 1996-01-11 | 1999-01-26 | Novo Nordisk As | Use of the l-enantiomer of centchroman for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of breast cancer |
US5726202A (en) | 1996-01-11 | 1998-03-10 | Novo Nordisk A/S | Benign prostatic hypertrophy |
AU1367297A (en) | 1996-01-11 | 1997-08-01 | Novo Nordisk A/S | Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical comp osition for the treatment or prophylaxis of menopausal symptoms |
US5773031A (en) | 1996-02-27 | 1998-06-30 | L. Perrigo Company | Acetaminophen sustained-release formulation |
IL120262A (en) | 1996-02-28 | 2001-01-28 | Pfizer | Droloxifene and derivatives thereof for use in increasing serum testosterone levels |
US5985910A (en) | 1996-04-19 | 1999-11-16 | American Home Products Corporation | 3- [4- (2- Phenyl-Indole-1-ylmethyl) Phenyl]- Acrylamides as estrogenic agents |
US5880137A (en) | 1996-04-19 | 1999-03-09 | American Home Products Corporation | 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents |
US5998402A (en) | 1996-04-19 | 1999-12-07 | American Home Products Corporation | 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents |
US5780497A (en) | 1996-04-19 | 1998-07-14 | American Home Products Corporation | 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents |
DE19635525A1 (de) | 1996-08-20 | 1998-02-26 | Schering Ag | 7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln |
WO1998018610A1 (en) | 1996-10-28 | 1998-05-07 | Lengerich Bernhard H Van | Embedding and encapsulation of controlled release particles |
AU741145B2 (en) | 1997-04-03 | 2001-11-22 | Eisai Inc. | Biodegradable terephthalate polyester-poly(phosphate) polymers, compositions, articles, and methods for making and using the same |
ZA982818B (en) | 1997-04-09 | 1999-10-04 | Lilly Co Eli | Prevention of breast cancer using selective estrogen receptor modulators. |
ZA982877B (en) | 1997-04-09 | 1999-10-04 | Lilly Co Eli | Treatment of central nervous system disorders with selective estrogen receptor modulators. |
ZA982819B (en) | 1997-04-09 | 1999-10-04 | Lilly Co Eli | Treatment or prophylaxis of prostatic cancer and benign prostatic hyperplasia with selective estrogn receptor modulators. |
US6653297B1 (en) | 1997-07-03 | 2003-11-25 | Medical College Of Hampton Roads | Control of selective estrogen receptor modulators |
ES2239793T3 (es) | 1997-08-07 | 2005-10-01 | Eli Lilly And Company | Compuestos de 1-(4-(alcoxi sustituido)bencil)naftaleno con actividad inhibidora de estrogenos. |
US6342250B1 (en) | 1997-09-25 | 2002-01-29 | Gel-Del Technologies, Inc. | Drug delivery devices comprising biodegradable protein for the controlled release of pharmacologically active agents and method of making the drug delivery devices |
PE20000129A1 (es) | 1997-12-23 | 2000-03-11 | Schering Ag | 11 beta-halogeno-estratrienos sustituidos en 7 alfa, asi como el procedimiento para elaborar preparados farmaceuticos que contienen tales 11 beta-halogeno-estratrienos sustituidos en 7 alfa |
US6548491B2 (en) | 1997-12-24 | 2003-04-15 | Sri International | Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use |
US6054446A (en) | 1997-12-24 | 2000-04-25 | Sri International | Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use |
US6413533B1 (en) | 1998-05-07 | 2002-07-02 | The University Of Tennessee Research Corporation | Method for chemoprevention of prostate cancer |
US6069153A (en) | 1998-05-12 | 2000-05-30 | American Home Products Corporation | Indenoindoles and benzocarbazoles as estrogenic agents |
TR200100309T2 (tr) | 1998-07-30 | 2001-05-21 | Stoller Enterprises, Inc | Bitkilerin salisilik asit ve organik aminler ile muamelesi. |
ATE315033T1 (de) | 1998-08-07 | 2006-02-15 | Chiron Corp | Subtituierte isoxazole derivate als estrogen rezeptor modulatore |
WO2000007996A2 (en) | 1998-08-07 | 2000-02-17 | Chiron Corporation | Pyrazoles as estrogen receptor modulators |
US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
CO5180583A1 (es) | 1999-06-11 | 2002-07-30 | Watson Pharmaceuticals Inc | Administracion de esteroides androgenicos no orales a las mujeres |
AU6132700A (en) | 1999-09-30 | 2001-04-05 | Chienna B.V. | Polymers loaded with bioactive agents |
US6258802B1 (en) | 1999-10-06 | 2001-07-10 | Medical College Of Hampton Roads | Corticoid therapy |
TW593256B (en) | 1999-11-16 | 2004-06-21 | Hormos Medical Oy Ltd | Triphenylalkene derivatives and their use as selective estrogen receptor modulators |
WO2001052823A2 (en) | 2000-01-20 | 2001-07-26 | Noven Pharmaceuticals, Inc. | Compositions to effect the release profile in the transdermal administration of drugs |
US6340774B1 (en) | 2000-01-31 | 2002-01-22 | The Board Of Trustees Of The Leland Stanford Junior University | Non-steroidal estrogen-receptor antagonists |
DE10013782A1 (de) | 2000-03-15 | 2001-10-18 | Schering Ag | 4-Fluoralkyl-2H-benzopyrane mit antiestrogener Wirksamkeit, Verfahren zu ihrer Herstellung, pharmazeutische Präparate, die diese enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln |
AU2001261684B2 (en) | 2000-05-26 | 2006-01-12 | Harry Fisch | Methods of treating androgen deficiency in men using selective antiestrogens |
US7067557B2 (en) | 2000-05-26 | 2006-06-27 | Harry Fisch | Methods of treating androgen deficiency in men using selective antiestrogens |
WO2001098322A1 (en) | 2000-06-22 | 2001-12-27 | Northeastern University | Novel steroidal antiestrogens and antiandrogens and uses thereof |
ATE278421T1 (de) | 2000-08-11 | 2004-10-15 | Wyeth Corp | Verfahren zur behandlung eines östrogenrezeptor positives karzinoms |
US6503894B1 (en) | 2000-08-30 | 2003-01-07 | Unimed Pharmaceuticals, Inc. | Pharmaceutical composition and method for treating hypogonadism |
US6750213B2 (en) | 2000-10-19 | 2004-06-15 | Merck & Co., Inc. | Estrogen receptor modulators |
WO2002055020A2 (en) | 2000-12-11 | 2002-07-18 | Testocreme Llc | Topical testosterone formulations and associated methods |
US6599921B2 (en) | 2001-02-22 | 2003-07-29 | Nanodesign, Inc. | Non-steroidal estrogen receptor ligands |
WO2003005954A2 (en) | 2001-07-09 | 2003-01-23 | Zonagen, Inc. | Methods and materials for the treatment of testosterone deficiency in men |
US7173064B2 (en) | 2001-07-09 | 2007-02-06 | Repros Therapeutics Inc. | Methods and compositions with trans-clomiphene for treating wasting and lipodystrophy |
US6645974B2 (en) | 2001-07-31 | 2003-11-11 | Merck & Co., Inc. | Androgen receptor modulators and methods for use thereof |
EE200400061A (et) | 2001-08-11 | 2004-04-15 | Bristol-Myers Squibb Pharma Company | Trifenüületüleeni derivaadid kui selektiivsed östrogeeniretseptori modulaatorid ja neid sisaldavad ravimkoostised |
US7157604B2 (en) | 2001-08-13 | 2007-01-02 | Merck & Co., Inc. | Selective estrogen receptor modulators |
AU2002330031B2 (en) | 2001-09-21 | 2007-07-05 | Merck & Co., Inc. | Androstanes as androgen receptor modulators |
US20060269611A1 (en) | 2001-11-29 | 2006-11-30 | Steiner Mitchell S | Prevention and treatment of androgen-deprivation induced osteoporosis |
US7105679B2 (en) | 2001-12-19 | 2006-09-12 | Kanojia Ramesh M | Heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators |
SI1501819T1 (sl) | 2002-04-24 | 2011-01-31 | Merck Sharp & Dohme | Modulatorji estrogen receptorjev |
EP1776098A1 (en) * | 2004-07-14 | 2007-04-25 | Repros Therapeutics Inc. | Trans-clomiphene for the treatment of benign prostate hypertrophy, prostate cancer, hypogonadism, elevated triglycerides and high cholesterol |
AR051597A1 (es) | 2004-11-01 | 2007-01-24 | Merck & Co Inc | Moduladores de los receptores de estrogeno |
AU2006210481B2 (en) * | 2005-02-04 | 2011-12-08 | Repros Therapeutics Inc. | Methods and materials with trans-clomiphene for the treatment of male infertility |
JP2008537538A (ja) | 2005-02-11 | 2008-09-18 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Vegf拮抗剤及び降圧剤の治療的組み合わせ |
EP1865938A4 (en) | 2005-03-22 | 2008-09-24 | Repros Therapeutics Inc | DOSAGE SCHEMES FOR TRANS-CLOMIPHENE |
BRPI0615165A2 (pt) | 2005-08-05 | 2016-09-13 | Repros Therapeutics Inc | método de tratamento de infertilidade |
EP1829534A1 (en) * | 2006-03-02 | 2007-09-05 | Laboratorios Del Dr. Esteve, S.A. | Use of compounds binding to the sigma receptor for the treatment of metabolic syndrome |
CN102940619A (zh) | 2007-10-16 | 2013-02-27 | 利普生物药剂公司 | 用于治疗代谢综合征的珠氯米芬 |
-
2008
- 2008-09-05 CN CN2012103221933A patent/CN102940619A/zh active Pending
- 2008-09-05 WO PCT/US2008/075433 patent/WO2009051908A1/en active Application Filing
- 2008-09-05 MX MX2010004195A patent/MX2010004195A/es active IP Right Grant
- 2008-09-05 ES ES14185222T patent/ES2718912T3/es active Active
- 2008-09-05 KR KR20107009548A patent/KR101493472B1/ko not_active IP Right Cessation
- 2008-09-05 NZ NZ591955A patent/NZ591955A/en not_active IP Right Cessation
- 2008-09-05 EA EA201070477A patent/EA017385B1/ru not_active IP Right Cessation
- 2008-09-05 MY MYPI2010001513A patent/MY150082A/en unknown
- 2008-09-05 SG SG2012077103A patent/SG185311A1/en unknown
- 2008-09-05 CA CA2702710A patent/CA2702710C/en not_active Expired - Fee Related
- 2008-09-05 EA EA201200968A patent/EA022760B1/ru not_active IP Right Cessation
- 2008-09-05 UA UAA201005856A patent/UA96076C2/ru unknown
- 2008-09-05 CA CA2806526A patent/CA2806526C/en not_active Expired - Fee Related
- 2008-09-05 CA CA2866905A patent/CA2866905C/en not_active Expired - Fee Related
- 2008-09-05 NZ NZ585389A patent/NZ585389A/en not_active IP Right Cessation
- 2008-09-05 CN CN2008801214725A patent/CN101896174B/zh not_active Expired - Fee Related
- 2008-09-05 EP EP14185222.8A patent/EP2826475B1/en not_active Not-in-force
- 2008-09-05 BR BRPI0818637 patent/BRPI0818637A2/pt not_active Application Discontinuation
- 2008-09-05 EP EP08839098A patent/EP2211848A1/en not_active Withdrawn
- 2008-09-05 JP JP2010530005A patent/JP5558358B2/ja not_active Expired - Fee Related
- 2008-09-05 US US12/205,456 patent/US8372887B2/en active Active
- 2008-09-05 ME MEP-2010-65A patent/ME00996B/me unknown
- 2008-10-09 CL CL2008002999A patent/CL2008002999A1/es unknown
- 2008-10-15 TW TW097139463A patent/TW200918093A/zh unknown
- 2008-10-16 AR ARP080104518A patent/AR069541A1/es unknown
-
2010
- 2010-04-08 CO CO10040524A patent/CO6270215A2/es not_active Application Discontinuation
- 2010-04-12 NI NI201000053A patent/NI201000053A/es unknown
- 2010-04-13 IL IL205053A patent/IL205053A/en not_active IP Right Cessation
- 2010-04-15 EC EC2010010106A patent/ECSP10010106A/es unknown
- 2010-05-07 CR CR11418A patent/CR11418A/es not_active Application Discontinuation
-
2011
- 2011-04-18 HK HK11103866.2A patent/HK1150023A1/xx not_active IP Right Cessation
- 2011-08-02 US US13/196,688 patent/US8377991B2/en active Active
-
2014
- 2014-06-03 JP JP2014114963A patent/JP5856652B2/ja not_active Expired - Fee Related
-
2015
- 2015-12-10 JP JP2015241230A patent/JP2016040328A/ja active Pending
-
2017
- 2017-06-26 JP JP2017123973A patent/JP2017160273A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR11418A (es) | Trans-clomifeno para el sindrome metabolico | |
CL2018000318A1 (es) | Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925) | |
DOP2016000250A (es) | Una forma amorfa y una cristalina de hemitartrato genz 112638 como inhibidor de glucosilceramida sintasa | |
GT201400111A (es) | Triazolopiridinas sustituidas | |
UY32989A (es) | Coposiciones terapéuticas concentradas de fosfolípidos | |
CR11510A (es) | Uso de un inhibidor de la gamma-secretasa para tratamiento del cancer | |
AR077629A1 (es) | Mimetico de smac | |
CL2011000835A1 (es) | Compuestos derivados de espiro-oxindol; moduladores de los canales de sodio; composicion farmaceutica que comprende a dicho compuesto; y uso en el tratamiento del dolor, depresion, enfermedades cardiovasculares, respiratorias, psiquiatricas, entre otras. | |
CL2013003454A1 (es) | Composicion farmacéutica para prevenir o tratar diabetes que comprende un conjugado de insulina de accion prolongada y un conjugado de peptido insulinotropico de accion prolongada. | |
PE20141906A1 (es) | Esketamina para el tratamiento de la depresion refractaria al tratamiento o resistente al tratamiento | |
CL2013001104A1 (es) | Composicion farmaceutica que comprende un inhibidor de sglt2 y una insulina; y uso para tratar una enfermedad o afeccion tal como diabetes mellitus, diabetes mellitus tipo 1 y 2, entre otras. | |
CL2012000248A1 (es) | Compuesto conjugado de insulina; procedimiento de preparacion; composicion farmaceutica que lo comprende; combinacion farmaceutica; kit farmaceutico; uso en el tratamiento de trastornos mediados por insulina. | |
CL2012000620A1 (es) | Formulaciones farmaceuticas de un anticuerpo anti cd-20; uso de la formulacion para tratar enfermedad o trastorno que pueda corregirse mediante tratamiento con anticuerpo anti-cd20. | |
BR112015020466A8 (pt) | inibidores de cdc7, seus usos, e composição farmacêutica | |
CL2009000882A1 (es) | Un compuesto n-(4-cloro-3-(piridin-2-il)fenil)-4-(2-hidroxi-2-metilpropilsulfonil)-2-metilbenzamida, inhibidor de la via de señalización hedgehog; composición farmacéutica que comprende a dicho compuesto; y su uso para tratar el cancer. | |
CL2014000428A1 (es) | Metodo para el tratamiento de hepatitis c (hcv) que comprende administrar un compuesto de formula (i), (ii) o (iii) en combinacion con uno o mas agentes terapeuticos; composicion farmaceutica. | |
CU20120171A7 (es) | Triazolopiridinas sustituidas | |
HN2012000031A (es) | Terapia de combinacion para el tratamiento de la diabetes | |
AR065392A1 (es) | Metodos para el tratamiento por inhalacion de una enfermedad o estado respiratorio | |
AR061122A1 (es) | Regimen de cladribina para tratar la escleorosis multiple | |
CL2009000388A1 (es) | Compuestos derivados de biciclos nitrogenados; proceso de preparacion; composicion farmaceutica; y su uso para tratar el dolor cronico que surge por inflamacion o neuropatia. | |
CL2009000803A1 (es) | Uso de una variante de igf-1 pegilada para tratar, prevenir un trastorno neuromuscular; metodo para el tratamiento, prevencion y/o demora de un trastorno neuromuscular; composicion que comprende la variante de igf-1 modificada | |
AR085616A1 (es) | Composicion farmaceutica inhalable que comprende glicopirrolato, uso | |
CO2017006898A2 (es) | Formulación de relación fija de insulina glargina/lixisenatida | |
MX2012005689A (es) | Analogos de acido araquidonico y metodos para el tratamiento analgesico utilizando los mismos. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |